Valamehr Bahram's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Dec 14, 2021
- Accession no.
- 0001209191-21-069415
- Filed
- Dec 14, 2021
- Trade date
- Dec 13, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.19M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Valamehr BahramCIK 0001748177 | Officer (Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 13, 2021 | Common Stock | MOption exerciseAcquired | +25,000 | $2.73 | +$68,250 | 181,698 | Direct | |
| Dec 13, 2021 | Common Stock | SSaleDisposed | −2,100 | $45.68F2 | −$95,928 | 179,598 | Direct | |
| Dec 13, 2021 | Common Stock | SSaleDisposed | −7,018 | $46.72F3 | −$327,880.96 | 172,580 | Direct | |
| Dec 13, 2021 | Common Stock | SSaleDisposed | −6,564 | $47.61F4 | −$312,512.04 | 166,016 | Direct | |
| Dec 13, 2021 | Common Stock | SSaleDisposed | −7,718 | $48.75F5 | −$376,252.5 | 158,298 | Direct | |
| Dec 13, 2021 | Common Stock | SSaleDisposed | −1,600 | $49.27F6 | −$78,832 | 156,698 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 13, 2021 | Common Stock | MOption exerciseAcquired | +25,000 | $0.00 | $0 | 61,156 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $45.18 to $46.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $46.20 to $47.17 per share.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price of the shares sold from $47.21 to $48.20 per share.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price of the shares sold from $48.21 to $49.20 per share.
Referenced by the price of 1 transaction in Table I.
- F6
Represents the weighted average sale price of the shares sold from $49.21 to $49.40 per share.
Referenced by the price of 1 transaction in Table I.